Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 15/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2912464 | 0.98 | CYP19A1 (0.64) | CYP19A1TSHRMAPK1HIF1ATDP1 | |
| SCHEMBL1500533 | 0.80 | TSHR (0.50) | CYP19A1TSHRMAPK1HIF1ATDP1 | |
| Bromide SCHEMBL5873330 | 0.79 | CYP19A1 (0.66) | CYP19A1 | |
| SCHEMBL2914172 | 0.77 | CYP19A1 (0.68) | CYP19A1 | |
| SCHEMBL3299165 | 0.77 | CYP19A1 (0.68) | CYP19A1TSHRMAPK1HIF1ATDP1 | |
| SCHEMBL3274982 | 0.77 | CYP19A1 (1.00) | CYP19A1TSHRMAPK1HIF1ATDP1 | |
| SCHEMBL2912058 | 0.73 | CYP19A1 (0.64) | CYP19A1HPGD | |
| SCHEMBL3297715 | 0.72 | CYP19A1 (0.38) | CYP19A1TSHRMAPK1HIF1ATDP1 | |
| SCHEMBL1528588 | 0.72 | IDO1 (0.54) | CYP19A1TSHRMAPK1HIF1ATDP1 | |
| SCHEMBL8176557 | 0.71 | CYP19A1 (0.85) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132414-B2 | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation | AVENTIS PHARMA S.A. (FR) | 2006-11-07 | — | — | US | disclosed |
| US-20040157823-A1 | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation | AVENTIS PHARMA S.A. (FR) | 2004-08-12 | — | — | US | disclosed |
| US-6734176-B2 | ARE CB1-RECEPTOR ANTAGONISTS AND ARE USEFUL IN THE TREATMENT AND PREVENTION OF DISORDERS AFFECTING THE CENTRAL NERVOUS, IMMUNE, CARDIOVASCULAR OR ENDOCRINE, RESPIRATORY, GASTROINTESTINAL AND REPRODUCTIVE SYSTEMS; DRUG ABUSE | AVENTIS PHARMA S.A. (FR) | 2004-05-11 | — | — | US | disclosed |
| US-20030119810-A1 | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation | AVENTIS PHARMA S.A. (FR) | 2003-06-26 | — | — | US | disclosed |
| US-6566356-B2 | 3-amido or 3-sulfonylamino azetidine compounds and their preparation; high affinity for cannabinoid receptor CB1 type, useful in treating central nervous system, immune, gastrointestinal or cardiovascular disorders, drug abuse | AVENTIS PHARMA S.A. (FR) | 2003-05-20 | — | — | US | disclosed |
| US-6355631-B1 | TREATMENT OF PSYCHOSIS AND SCHIZOPHRENIA | AVENTIS PHARMA S.A. (FR) | 2002-03-12 | — | — | US | disclosed |
| US-20020019383-A1 | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation | AVENTIS PHARMA S.A. (FR) | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019383-A1 | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation | HRH2, ALK, HRH1 | ADRB2 66/4885CYP19A1 720/4885TSHR 799/4885 |
| US-20040157823-A1 | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation | ALK, HRH2, HRH1 | ADRB2 77/4885CYP19A1 919/4885TSHR 748/4885 |
| US-20030119810-A1 | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation | ALK, HRH2, HRH1 | ADRB2 77/4885CYP19A1 919/4885TSHR 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.